Effects of oxazepam on event-related brain potentials, EEG frequency bands, and vigilance performance. 1995

T H van Leeuwen, and M N Verbaten, and H S Koelega, and J L Slangen, and J van der Gugten, and G Camfferman
Department of Psychopharmacology, Faculty of Pharmacy, Rudolf Magnus Institute for Neuroscience, Utrecht University, The Netherlands.

Eighteen males performed two vigilance tasks with static and dynamic stimuli under the influence of oxazepam (20 and 40 mg) in a placebo-controlled, double blind, crossover design. Oxazepam dose-dependently impaired overall level of performance and aggravated the decrement with time in measures of accuracy and sensitivity relative to placebo. The drug reduced the amplitudes of the P1, N1, P2N2, and P3 (dose-dependently) waves of event-related potentials (ERPs). Oxazepam aggravated the linear decline with time of the P3 amplitude only. Oxazepam impaired accuracy was related to deterioration of central processing involved in stimulus discrimination (P2N2). Impairment of response-related performance measures (RT and RI) was associated with processing manifest in the P1, N1, and P3 waves. Oxazepam effects on the amplitudes of N1 and P3 correlated with drug effects on power in alpha 1 (8-10 Hz). Drug effects on overall performance and alpha were also related; the drug effect on response speed correlated only with the drug effect on beta 1 (12.5-21 Hz). Effects of time-on-task on performance and EEG were unrelated, but oxazepam induced performance declines with time may have been caused by declines in resource allocation, as manifest in the amplitude of P3. Time effects on EEG power bands and ERP amplitudes were not significantly related to the time course of oxazepam activity. A curious dissociation emerged: both oxazepam and time-on-task impaired performance, but the drug induced a decrease of theta and alpha 1 power, whereas time-on-task increased power. Various processes play a role in performance decrements with time, and various aspects of processing may be involved in signal-detection measures which makes terms such as sensitivity quite meaningless. So-called computational processing was indistinguishable from energetic processes, which questions the validity of the distinction between these two domains. Explanations of EEG activity in terms of a unidimensional theory of arousal are untenable.

UI MeSH Term Description Entries
D008297 Male Males
D010076 Oxazepam A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia. Adumbran,Serax,Tazepam
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004569 Electroencephalography Recording of electric currents developed in the brain by means of electrodes applied to the scalp, to the surface of the brain, or placed within the substance of the brain. EEG,Electroencephalogram,Electroencephalograms
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001364 Awareness The act of "taking account" of an object or state of affairs. It does not imply assessment of, nor attention to the qualities or nature of the object. Situation Awareness,Situational Awareness,Awareness, Situation,Awareness, Situational,Awarenesses,Awarenesses, Situation,Awarenesses, Situational,Situation Awarenesses,Situational Awarenesses
D018757 GABA Modulators Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. gamma-Aminobutyric Acid Modulators,GABAergic Modulators,Acid Modulators, gamma-Aminobutyric,Modulators, GABA,Modulators, GABAergic,Modulators, gamma-Aminobutyric Acid,gamma Aminobutyric Acid Modulators
D018913 Event-Related Potentials, P300 A late-appearing component of the event-related potential. P300 stands for a positive deflection in the event-related voltage potential at 300 millisecond poststimulus. Its amplitude increases with unpredictable, unlikely, or highly significant stimuli and thereby constitutes an index of mental activity. (From Campbell, Psychiatric Dictionary, 6th ed) Evoked Potentials, P300 Component,P3 Event Related Potential,P300 Event-Related Potential,P300 Event-Related Potentials,Event-Related Potentials, P3,P3 Event-Related Potentials,P300 Component,P3a Event-Related Potentials,P3b Event-Related Potentials,Event Related Potentials, P3,Event Related Potentials, P300,Event-Related Potential, P3,Event-Related Potential, P300,Event-Related Potential, P3a,Event-Related Potential, P3b,Event-Related Potentials, P3a,Event-Related Potentials, P3b,P3 Event Related Potentials,P3 Event-Related Potential,P300 Components,P300 Event Related Potential,P300 Event Related Potentials,P3a Event Related Potentials,P3a Event-Related Potential,P3b Event Related Potentials,P3b Event-Related Potential

Related Publications

T H van Leeuwen, and M N Verbaten, and H S Koelega, and J L Slangen, and J van der Gugten, and G Camfferman
June 1991, Perceptual and motor skills,
T H van Leeuwen, and M N Verbaten, and H S Koelega, and J L Slangen, and J van der Gugten, and G Camfferman
May 2011, Psychopharmacology,
T H van Leeuwen, and M N Verbaten, and H S Koelega, and J L Slangen, and J van der Gugten, and G Camfferman
March 1979, Pharmakopsychiatrie, Neuro-Psychopharmakologie,
T H van Leeuwen, and M N Verbaten, and H S Koelega, and J L Slangen, and J van der Gugten, and G Camfferman
June 1999, Pharmacology, biochemistry, and behavior,
T H van Leeuwen, and M N Verbaten, and H S Koelega, and J L Slangen, and J van der Gugten, and G Camfferman
January 2004, Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology,
T H van Leeuwen, and M N Verbaten, and H S Koelega, and J L Slangen, and J van der Gugten, and G Camfferman
February 1986, Journal of abnormal psychology,
T H van Leeuwen, and M N Verbaten, and H S Koelega, and J L Slangen, and J van der Gugten, and G Camfferman
October 2000, Neuroreport,
T H van Leeuwen, and M N Verbaten, and H S Koelega, and J L Slangen, and J van der Gugten, and G Camfferman
April 2006, Brain research,
T H van Leeuwen, and M N Verbaten, and H S Koelega, and J L Slangen, and J van der Gugten, and G Camfferman
December 2001, Neuroreport,
T H van Leeuwen, and M N Verbaten, and H S Koelega, and J L Slangen, and J van der Gugten, and G Camfferman
October 2006, Journal of neuroscience methods,
Copied contents to your clipboard!